Summary & Overview
HCPCS J0888: Injection, epoetin beta, 1 microgram (non-ESRD)
HCPCS Level II code J0888 denotes a 1-microgram injection of epoetin beta for non-ESRD indications. As an erythropoiesis-stimulating agent, epoetin beta is used to manage anemia related to chemotherapy, chronic disease, or other non-dialysis clinical contexts. This code is important nationally because it standardizes billing for a high-cost biologic administered in outpatient and infusion settings and affects clinical workflow, reimbursement, and utilization oversight.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of coding and clinical context, payer coverage considerations, and commonly reported billing practices. The publication summarizes typical sites of service and service line implications for administering a parenteral biologic, and it outlines which stakeholders—payers, providers, and hospital administrators—are affected by coding choices.
This piece provides benchmarks and practical context for claims processing, highlights potential policy drivers that influence coverage and prior authorization, and clarifies where clinicians and billing staff should confirm clinical indication and documentation. Data not available in the input are noted where applicable.
Billing Code Overview
HCPCS Level II code J0888 describes an injection of epoetin beta, 1 microgram, intended for non-ESRD (non-end-stage renal disease) use. This product is a therapeutic erythropoiesis-stimulating agent used to treat anemia associated with medical conditions other than chronic dialysis-dependent renal failure.
Service Type: Parenteral medication administration
Typical Site of Service: Outpatient clinics, physician offices, oncology and hematology infusion centers, and hospital outpatient departments
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with chemotherapy-induced anemia or anemia due to chronic disease (non-ESRD) receiving subcutaneous or intravenous epoetin beta therapy to raise hemoglobin and reduce transfusion needs. The patient is seen in an oncology infusion clinic, hematology outpatient clinic, or hospital outpatient department. The prescribing clinician (medical oncologist or hematologist) documents baseline hemoglobin, iron studies, transfusion history, and treatment intent. Nursing verifies dose, prepares the injectable vial or syringe, and administers J0888 per manufacturer dosing (billed per microgram units). Clinical monitoring includes vital signs during administration, periodic hemoglobin checks, and dose adjustments. Billing uses the HCPCS Level II code J0888 for the drug units administered; documentation must support indication, dose, route, date of service, and supervising provider. Typical sites of service are outpatient infusion centers, physician offices, and hospital outpatient departments. Common clinical modifiers and payer-specific requirements are applied at claim submission as appropriate.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
JW | Drug discarded/partial dose | Use when part of a single-dose vial is discarded and the payer requires reporting of wasted biologic |